Gross Adam's most recent trade in Adma Biologics Inc was a trade of 15,000 Common Stock done at an average price of $19.8 . Disclosure was reported to the exchange on Dec. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.79 per share. | 15 Dec 2025 | 15,000 | 2,013,850 (2%) | 0% | 19.8 | 296,850 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Dec 2025 | 15,000 | 2,028,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 15,000 | 720,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.79 per share. | 15 Dec 2025 | 6,000 | 2,007,850 (2%) | 0% | 19.8 | 118,740 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Sale or transfer of securities back to the company at price $ 7.85 per share. | 24 Nov 2025 | 333,557 | 0 | - | 7.9 | 2,618,428 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 19 Nov 2025 | 15,000 | 2,034,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2025 | 15,000 | 735,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 19 Nov 2025 | 15,000 | 2,019,850 (2%) | 0% | 16 | 240,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 19 Nov 2025 | 6,000 | 2,013,850 (2%) | 0% | 16 | 96,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 24 Oct 2025 | 15,000 | 2,040,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Oct 2025 | 15,000 | 750,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 24 Oct 2025 | 15,000 | 2,025,850 (2%) | 0% | 16 | 240,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 24 Oct 2025 | 6,000 | 2,019,850 (2%) | 0% | 16 | 96,000 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 7.80 per share. | 23 Oct 2025 | 1,762 | 333,557 | - | 7.8 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.13 per share. | 15 Sep 2025 | 15,000 | 2,031,850 (2%) | 0% | 16.1 | 241,950 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Sep 2025 | 15,000 | 2,046,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2025 | 15,000 | 765,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.13 per share. | 15 Sep 2025 | 6,000 | 2,025,850 (2%) | 0% | 16.1 | 96,780 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Aug 2025 | 15,000 | 2,052,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 15,000 | 780,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.88 per share. | 15 Aug 2025 | 15,000 | 2,037,850 (2%) | 0% | 16.9 | 253,200 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.88 per share. | 15 Aug 2025 | 6,000 | 2,031,850 (2%) | 0% | 16.9 | 101,280 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 3.96 per share. | 17 Jul 2025 | 3,472 | 331,794 | - | 4.0 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Jul 2025 | 15,000 | 2,058,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 15,000 | 795,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.66 per share. | 15 Jul 2025 | 15,000 | 2,043,850 (2%) | 0% | 18.7 | 279,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.66 per share. | 15 Jul 2025 | 6,000 | 2,037,850 (2%) | 0% | 18.7 | 111,960 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 44,444 | 328,322 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 16 Jun 2025 | 15,000 | 2,049,850 (2%) | 0% | 20.8 | 312,150 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 15,000 | 810,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 16 Jun 2025 | 15,000 | 2,064,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 16 Jun 2025 | 6,000 | 2,043,850 (2%) | 0% | 20.8 | 124,860 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 May 2025 | 15,000 | 2,070,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 15,000 | 825,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 15 May 2025 | 15,000 | 2,055,850 (2%) | 0% | 19.5 | 291,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 15 May 2025 | 6,000 | 2,049,850 (2%) | 0% | 19.5 | 116,700 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 15,000 | 840,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.46 per share. | 15 Apr 2025 | 15,000 | 2,061,850 (2%) | 0% | 21.5 | 321,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Apr 2025 | 15,000 | 2,076,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.46 per share. | 15 Apr 2025 | 6,000 | 2,055,850 (2%) | 0% | 21.5 | 128,760 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 4.88 per share. | 10 Apr 2025 | 2,817 | 283,878 | - | 4.9 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 19 Mar 2025 | 15,000 | 2,082,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2025 | 15,000 | 855,950 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 19 Mar 2025 | 15,000 | 2,067,850 (2%) | 0% | 18.9 | 283,800 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 19 Mar 2025 | 6,000 | 2,061,850 (2%) | 0% | 18.9 | 113,520 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.91 per share. | 06 Mar 2025 | 56,438 | 2,097,363 (2%) | 0% | 16.9 | 954,367 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.02 per share. | 06 Mar 2025 | 29,513 | 2,067,850 (2%) | 0% | 17.0 | 502,311 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.78 per share. | 25 Feb 2025 | 54,867 | 2,153,801 (2%) | 0% | 15.8 | 865,801 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.44 per share. | 25 Feb 2025 | 18,018 | 2,208,668 (2%) | 0% | 15.4 | 278,198 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 376,744 | 376,744 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 252,022 | 2,226,686 (2%) | 0% | 0 | Common Stock | |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 6.26 per share. | 16 Jan 2025 | 2,196 | 281,061 | - | 6.3 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.15 per share. | 31 Dec 2024 | 14,343 | 1,974,664 (2%) | 0% | 17.1 | 245,982 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.10 per share. | 22 Nov 2024 | 48,967 | 1,989,007 (2%) | 0% | 21.1 | 1,033,204 | Common Stock |
| Vimeo Inc | Gross Adam | Director | Grant, award, or other acquisition of securities at price $ 4.89 per share. | 10 Oct 2024 | 2,811 | 278,864 | - | 4.9 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.99 per share. | 30 Sep 2024 | 21,752 | 2,037,974 (2%) | 0% | 20.0 | 434,822 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.35 per share. | 01 Sep 2024 | 6,194 | 276,052 | - | 5.4 | 33,138 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.29 per share. | 26 Aug 2024 | 389,356 | 2,059,726 (2%) | 0% | 17.3 | 6,732,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 341,960 | 741,020 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 26 Aug 2024 | 341,960 | 2,401,686 (2%) | 0% | 3.4 | 1,145,566 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.69 per share. | 26 Aug 2024 | 236,889 | 2,059,726 (2%) | 0% | 17.7 | 4,191,088 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 26 Aug 2024 | 64,405 | 2,124,131 (2%) | 0% | 3.4 | 215,757 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 64,405 | 1,082,980 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 60,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.80 per share. | 26 Aug 2024 | 60,000 | 2,296,615 (2%) | 0% | 10.8 | 648,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 55,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Aug 2024 | 55,000 | 2,179,131 (2%) | 0% | 5 | 275,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 47,396 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.91 per share. | 26 Aug 2024 | 47,396 | 2,449,082 (2%) | 0% | 2.9 | 138,159 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 40,500 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.37 per share. | 26 Aug 2024 | 40,500 | 2,236,615 (2%) | 0% | 9.4 | 379,485 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 16,984 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.96 per share. | 26 Aug 2024 | 16,984 | 2,196,115 (2%) | 0% | 6.0 | 101,225 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Purchase of securities on an exchange or from another person at price $ 5.01 per share. | 12 Aug 2024 | 50,000 | 282,246 | - | 5.0 | 250,400 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.81 per share. | 01 Aug 2024 | 6,194 | 232,246 | - | 3.8 | 23,599 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 3.63 per share. | 18 Jul 2024 | 3,186 | 238,440 | - | 3.6 | 11,566 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.83 per share. | 01 Jul 2024 | 6,194 | 235,254 | - | 3.8 | 23,723 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.18 per share. | 30 Jun 2024 | 21,752 | 2,059,726 (2%) | 0% | 11.2 | 243,187 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 44,444 | 241,448 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Other type of transaction at price $ 3.21 per share. | 14 Jun 2024 | 460,000 | 2,191,475 (2%) | 0% | 3.2 | 1,476,600 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Sale of securities on an exchange or to another person at price $ 10.72 per share. | 14 Jun 2024 | 100,000 | 2,081,475 (2%) | 0% | 10.7 | 1,071,980 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jun 2024 | 10,000 | 2,181,475 (2%) | 0% | 0 | Common Stock | |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 01 Jun 2024 | 6,194 | 197,004 | - | 3.9 | 24,033 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 01 May 2024 | 6,194 | 203,198 | - | 3.6 | 22,484 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.00 per share. | 01 Apr 2024 | 4,361 | 209,392 | - | 4 | 17,444 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.60 per share. | 31 Mar 2024 | 21,752 | 2,651,475 (3%) | 0% | 6.6 | 143,563 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 06 Mar 2024 | 55,003 | 2,701,990 (3%) | 0% | 6.1 | 336,618 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.16 per share. | 06 Mar 2024 | 28,763 | 2,673,227 (3%) | 0% | 6.2 | 177,180 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.01 per share. | 01 Mar 2024 | 4,361 | 213,753 | - | 5.0 | 21,849 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.36 per share. | 29 Feb 2024 | 9,588 | 2,756,993 (3%) | 0% | 5.4 | 51,392 | Common Stock |
| Adma Biologics Inc | S. Adam Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 870,950 | 870,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Grossman S. Adam | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 557,728 | 2,766,581 (3%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Grossman S. Adam | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.26 per share. | 25 Feb 2024 | 22,457 | 2,208,853 (2%) | 0% | 5.3 | 118,124 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.97 per share. | 01 Feb 2024 | 5,008 | 218,114 | - | 4.0 | 19,882 | Common Stock |
| Vimeo Inc | Gross Adam | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.92 per share. | 01 Jan 2024 | 5,008 | 223,122 | - | 3.9 | 19,631 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.52 per share. | 31 Dec 2023 | 23,057 | 2,231,310 (2%) | 0% | 4.5 | 104,218 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 01 Dec 2023 | 4,226 | 228,130 | - | 3.7 | 15,636 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.61 per share. | 15 Aug 2023 | 1,589,987 | 2,523,088 (2%) | 1% | 4.6 | 7,329,840 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 583,224 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. | 15 Aug 2023 | 583,224 | 4,623,544 (5%) | 0% | 3.7 | 2,134,600 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.54 per share. | 15 Aug 2023 | 510,469 | 4,113,075 (4%) | 0% | 4.5 | 2,318,959 | Common Stock |